Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22753064 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
Condition: Cystic Fibrosis
Interventions: Drug: TOBI™ Podhaler™ 112 mg inhaled twice daily;   Drug: Colistimethate 75 mg inhaled two times daily

Indicates status has not been verified in more than two years